Fasting plasma glucose, BMI elevated 10 years before diagnosis of prediabetes, diabetes
MONDAY, Oct. 22, 2018 (HealthDay News) — Individuals who develop diabetes or prediabetes have elevated fasting plasma glucose (FPG) at least 10 years before diagnosis, according to an observational study recently published in the Journal of the Endocrine Society.
Hiroyuki Sagesaka, M.D., from Aizawa Hospital in Matsumoto, Japan, and colleagues analyzed data from 27,392 health examinees without diabetes for a mean of 5.3 years. Ten years before diagnosis of prediabetes (4,781 participants) or diabetes (1,061 participants), trajectories of FPG, body mass index (BMI), and the single point insulin sensitivity estimator (SPISE), an index of insulin sensitivity, were assessed.
The researchers found that 10 years before diagnosis, mean FPG and BMI were significantly higher in individuals who developed diabetes (FPG, 101.5 versus 94.5 mg/dL; BMI, 24.0 versus 22.7 kg/m²), while SPISE was lower than among those who did not develop diabetes (SPISE, 7.32 versus 8.34; all P < 0.01). At 10 years before diagnosis, these measurements were slightly but significantly different in participants who developed prediabetes versus those who did not develop prediabetes (FPG, 91.8 versus 89.6 mg/dL; BMI, 22.6 versus 22.1 kg/m²; SPISE, 8.44 versus 8.82; all P < 0.01). Toward the time of diabetes or prediabetes diagnosis, the differences were progressively greater.
“Because trials of prevention in people with prediabetes seem to be less successful over long term follow up, we may need to intervene much earlier than the prediabetes stage to prevent progression to full blown diabetes,” Sagesaka said in a statement. “A much earlier intervention [trial], either drug or lifestyle related, is warranted.”
Pregnancy Complications Linked to Subsequent Risk for Cardiometabolic-Renal Conditions
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria
Genetics, Diabetes Tied to MASLD-Associated Cirrhosis Before Age 50
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis